globally for relapsing MS with the established therapy of TYSABRI, and counting2,a
The TOUCH® Prescribing Program helps you support patients throughout their treatment on TYSABRI
in the US who start TYSABRI have received no previous DMT3,b
Leading physicians describe the value of real-world experience (10+ years) when considering an appropriate DMT.
a190,800 patients as of August 2018.2
bAs of February 2019.3